Daoyin technique to boost exercise endurance in IPF

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter randomized controlled trial tests a guided Daoyin technique added to routine training for IPF patients, using digital rehabilitation tools to monitor movement, heart rate, and oxygen levels. The study compares guided technique plus standard training to standard training alone over 3 months, with a 3-month follow-up, and assesses endurance and lung function among other outcomes. Primary endpoints include the six-minute walk distance and a 30-second sit-to-stand test; secondary endpoints cover acute exacerbations, FVC, DLCO, VO2 peak, and patient-reported measures. Data are collected via motion capture, wearable sensors, and home-based training devices to inform rehabilitation tracking and effect evaluation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients who meet the diagnostic criteria for IPF;
2. Those who can tolerate guided - technique training;
3. Aged between 40 and 85 years old;
4. Those who can independently or with the assistance of family members use devices such as smartphones and computers during home - based training;
5. Those who voluntarily accept treatment and sign the informed consent form.

Exclusion Criteria:

1. Patients in the acute exacerbation phase of IPF.
2. Patients with comorbidities such as chronic obstructive pulmonary disease, lung cancer, active pulmonary tuberculosis, bronchiectasis, pulmonary embolism, and other pulmonary diseases.
3. Patients with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, cardiac function at grade 3 or above, stroke, cerebral hemorrhage, etc.).
4. Patients with severe liver diseases (such as bleeding caused by liver cirrhosis, portal hypertension, and esophagogastric varices) and severe kidney diseases (dialysis, kidney transplantation, etc.).
5. Patients with severe osteoarthropathy or osteoporosis, and those with unstable fractures.
6. Patients with progressive neuromuscular diseases.
7. Patients with unclear consciousness, dementia, and various mental illnesses.
8. Pregnant or lactating women, and patients with a recent pregnancy plan.
9. Patients who have been participating in other clinical trials within 1 month before enrollment.
10. Patients who need long - term use of ventilators and those with unstable vital signs while bedridden.

Where it's running

• Xiyuan Hospital of China Academy of Chinese Medical Sciences
  Beijing, Beijing Municipality, China Recruiting
• The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
  Zhengzhou, Henan, China Recruiting
• The Affiliated Hospital of Liaoning University of Traditional Chinese Medicinenese Medicine
  Shenyang, Liaoning, China Recruiting

Study contacts

• Study coordinator: Li-Jian Pang, Ph.D
• Email: 1605893852@qq.com
• Phone: +8615042457760

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• New IPF drug ORJ-001 tested in adults with IPF

  A phase 2 study tests ORJ-001 versus placebo in adults with idiopathic pulmonary fibrosis to see if it is tolerated and whether it helps lung function.

  Recruiting at 2 sites Phase 2 Oorja Bio, Inc. · Doral, Florida and 1 other locations · NCT07869147

• Nalbuphine ER for IPF-related chronic cough

  This study tests whether extended-release nalbuphine tablets can reduce chronic cough in people with idiopathic pulmonary fibrosis.

  Recruiting at 4 sites Phase 3 Trevi Therapeutics · Wilmington, Delaware and 3 other locations · NCT07868419

• Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients

  This observational study tests how fast patients with IPF or PPF can inhale through dry powder inhalers with different resistances.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07820254

• Photon-counting CT vs standard HRCT to help diagnose IPF and other ILDs

  This study tests whether photon-counting CT can improve identifying IPF and other ILDs compared with standard HRCT for patients discussed in multidisciplinary teams.

  Recruiting Istituto Clinico Humanitas · Rozzano, Italy · NCT07790614

• Rentosertib by mouth for people with idiopathic pulmonary fibrosis

  This is a randomized, placebo-controlled test to see if Rentosertib helps adults with idiopathic pulmonary fibrosis when taken as a pill.

  Recruiting at 12 sites Phase 3 InSilico Medicine Hong Kong Limited · Hefei, Anhui and 46 other locations · NCT07687459

• Inhaled nintedanib powder for IPF in adults

  This study tests whether an inhaled form of nintedanib can safely help adults with idiopathic pulmonary fibrosis.

  Recruiting Phase 2 Mannkind Corporation · Windsor, Ontario · NCT07679893

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.